Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01796457 · ClinicalTrials.gov registry record
HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B
A clinical trial of Hepatitis B, sponsored by University of Pennsylvania.
- Active
- Registry status
- 40
- Enrollment target
- 8
- Study locations
NCT01796457 is a study of Hepatitis B that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 40 participants, below the 1,627-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT01796457, a study of Hepatitis B, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an ancillary to the NIDDK-sponsored treatment trials titled: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B (NCT01369212) and Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B (NCT01369199). This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected participants enrolled in the HBRN's clinical trials (NCT01369212 and NCT01369199) to define natural history and treatment outcome.
Conditions Studied
Study Locations (8)
California
- California Pacific Medical Center - San Francisco
- University of California San Francisco Medical Center - San Francisco
Washington
- Virginia Mason Medical Center - Seattle
- Harborview Medical Center - Seattle
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- University of Minnesota - Plymouth
Virginia
- Virginia Commonwealth University Medical Center - Richmond
Ontario
- Toronto Western Hospital Liver Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-03 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01796457
The ClinicalTrials.gov registry entry for NCT01796457 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,627-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 0 interventions.
NCT01796457 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Washington, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01796457 about?
NCT01796457 is a clinical study titled "HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B". This is an ancillary to the NIDDK-sponsored treatment trials titled: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B (NCT01369212) and Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With C...
What is the current status of trial NCT01796457?
This trial is currently active not recruiting. The enrollment target is 40 participants. The study started on 2013-03. Estimated completion is 2026-12-01.
What conditions does trial NCT01796457 study?
This clinical trial studies the following conditions: Hepatitis B.
Who is sponsoring clinical trial NCT01796457?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01796457 being conducted?
This trial has 8 study locations across California, Massachusetts, Minnesota, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
RECRUITING · Phase 2
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
RECRUITING · Phase 4
-
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.